VICTORIA, British Columbia, Aug. 12, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals, Inc., (TSX:AUP) today announced that its Chief Operating Officer Michael R. Martin will present a corporate overview of the company at the Canaccord Genuity 34th Annual Growth Conference, taking place August 13-14 in Boston at the Intercontinental Hotel.
Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. It is currently in the recruitment and enrollment phase of its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (LN). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.
Visit www.auriniapharma.com for more information. CONTACT: Company Contact: Stephen Zaruby President & Chief Executive Officer 250-708-4293 email@example.com Investor & Media Contact: Michael R. Martin Chief Operating Officer 250-708-4272 firstname.lastname@example.org
Help employers find you! Check out all the jobs and post your resume.